CDXS vs MRVI
CDXS: Codexis utilizes proprietary directed evolution and machine learning to engineer high-performance enzymes that optimize the manufacturing of complex RNAi and small molecule therapeutics. MRVI: Maravai LifeSciences produces critical reagents and manufacturing services for mRNA vaccines and therapies, with CleanCap and TriLink products serving large biotech and pharmaceutical customers.
Side-by-side fundamentals
| Metric | CDXS | MRVI | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $1.40 | $6.57 | |
| Market cap as of 2026-08-03 | $127M | $1.7B | |
| Net margin as of 2026-08-03 | -41.0% | -51.1% | CDXS higher |
| Gross margin as of 2026-08-03 | +88.9% | +29.3% | CDXS higher |
| Operating margin as of 2026-08-03 | -37.5% | -82.2% | CDXS higher |
| ROE as of 2026-08-03 | -68.1% | -44.7% | MRVI higher |
| ROA as of 2026-08-03 | -23.7% | -13.0% | MRVI higher |
| Debt / equity as of 2026-08-03 | 0.94 | 1.28 | CDXS lower |
| Revenue growth (YoY) as of 2026-08-03 | +56.8% | -15.3% | CDXS higher |
| Revenue CAGR (3y) SEC XBRL | -20.2% | -40.5% | CDXS higher |
| Beta as of 2026-08-03 | 1.77 | 1.23 | |
| 1-year return as of 2026-07-31 close | -47.8% | +180.8% | MRVI higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.